Connect with us

Hi, what are you looking for?

Thursday, Oct 21, 2021
Mugglehead Magazine
Cannabis & psychedelics industry news based in Vancouver, B.C.
  • Loading stock data...

Business

Avicanna files patent for cannabinoid med that reduces epileptic seizures, sudden death

A number of the medical cannabis maker’s products are available to Canadian patients

Avicanna files patent for cannabinoid med that reduces epileptic seizures, sudden death
Image via Deposit Photos

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is moving to patent a novel cannabinoid formulation that reduces epilepsy-caused seizures and sudden death.

On Friday, the Toronto-based biopharmaceutical firm said it recently filed an application with the United States Patent and Trademark Office.

“Understanding the anti-convulsant properties of our proprietary formulation in seizure disorders is important particularly since this combination drug has potential to reduce the likelihood of seizure-induced sudden death in epilepsy,” CEO Aras Azadian said in a statement.

Epilepsy researcher Peter Carlen, from the Krembil Research Institute at the University Health Network in Toronto, tested the formulation in preliminary studies using mice, and found that the formulation was a more efficient anti-convulsant compared to CBD or THC alone.

“The exceptional research conducted by Dr. Carlen’s team with support from our R&D team, and the resulting patent submission will be a major driver for guiding our long-term drug and clinical development plans, particularly since its in the area with an existing Food and Drug Administration-approved cannabinoid-based drug,” Azadian added.

The cannabinoid-based formulation by Avicanna acts on the 5-HT1A receptor, which is known to be involved in seizures and epileptic events.

Read more: Sunnybrook Hospital’s medical cannabis program paves way for better patient access

Avicanna is the official provider for Toronto’s Sunnybrook Hospital, the first Canadian institution to sell cannabis products directly to patients. Under Canadian law, hospitals can dispense medical cannabis on site, which is otherwise not allowed.

Avicanna’s products are also available to patients registered with Medical Cannabis by Shoppers Drug Mart.

The company sells products including its medical line, RHO Phyto, which contains varying ratios of CBD and THC in oral, sublingual topical and transdermal formulations. It also makes Pura H&W, a functional CBD cosmetic and topical products line.

Its Santa Marta, Colombia-based subsidiary Aureus provides the raw materials for Avicanna and its global affiliates.

Avicanna has cannabinoid-based drug candidates in pre-clinical stages, which are focused on dermatology, pain management and other neurological disorders.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Natalia Buendia Calvillo on Twitter

natalia@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can

Canada

As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices

Analysis

While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe

Culture

Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance